Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Disorders of Sex Development

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    112 result(s) found for: Disorders of Sex Development. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2012-002477-59 Sponsor Protocol Number: CDGP1 Start Date*: 2012-12-12
    Sponsor Name:Taneli Raivio, Helsingin yliopistollinen keskussairaala
    Full Title: Constitutional Delay of Growth and Puberty: towards evidence-based treatment
    Medical condition: constitutional delay of puberty
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10012205 Delayed puberty PT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-001607-30 Sponsor Protocol Number: Debio8206-CPP-301 Start Date*: 2015-04-24
    Sponsor Name:Debiopharm International, S.A.
    Full Title: An open-label, non-comparative, multicenter study on the efficacy, safety, and pharmacokinetics of triptorelin pamoate (embonate) 22.5 mg 6-month formulation in patients suffering from central (gon...
    Medical condition: Central Precocious Puberty
    Disease: Version SOC Term Classification Code Term Level
    18.0 10014698 - Endocrine disorders 10058084 Precocious puberty PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-011186-88 Sponsor Protocol Number: ABB-09-001 Start Date*: 2009-09-08
    Sponsor Name:FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
    Full Title: Desarrollo de inhibidores en pacientes no tratados previamente (PUP) o en pacientes mínimamente tratados con componentes sanguíneos (MBCTP) al ser expuestos a concentrados de derivados plasmáticos ...
    Medical condition: El estudio es un ensayo clínico abierto, aleatorizado, controlado, prospectivo, multicéntrico, internacional e independiente sobre la frecuencia de formación de inhibidores en pacientes no tratados...
    Disease: Version SOC Term Classification Code Term Level
    9 10018937 Haemophilia A LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: ES (Prematurely Ended) IT (Completed) PT (Completed) FR (Ongoing) DE (Restarted) AT (Prematurely Ended) BE (Ongoing) GB (GB - no longer in EU/EEA) SK (Ongoing) CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004668-31 Sponsor Protocol Number: SPD503-318 Start Date*: 2012-03-14
    Sponsor Name:Shire Pharmaceutical Development Ltd
    Full Title: A Phase 3, Open-label, Multicentre, Protocol to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participat...
    Medical condition: Attention Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004873 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) AT (Completed) ES (Completed) IE (Completed) BE (Completed) IT (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000184-32 Sponsor Protocol Number: 205203 Start Date*: 2017-09-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622
    Medical condition: Hypereosinophilic syndrome (HES)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10048643 Hypereosinophilic syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) FR (Completed) PL (Completed) Outside EU/EEA IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-022384-35 Sponsor Protocol Number: CCX114644 Start Date*: 2011-02-02
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn’s Disease
    Medical condition: Subjects with Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended) HU (Prematurely Ended) GR (Prematurely Ended) AT (Completed) PL (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) EE (Completed) IT (Completed) SK (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018579-12 Sponsor Protocol Number: SPD503-316 Start Date*: 2011-01-26
    Sponsor Name:Shire Pharmaceutical Development Ltd
    Full Title: A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children...
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10068451 ADHD, combined type LLT
    14.1 10037175 - Psychiatric disorders 10068453 ADHD, predominantly inattentive type LLT
    14.1 10037175 - Psychiatric disorders 10068452 ADHD, predominantly hyperactive-impulsive type LLT
    14.1 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Prematurely Ended) FR (Completed) ES (Completed) SE (Completed) IE (Completed) AT (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005452-34 Sponsor Protocol Number: SPD489-406 Start Date*: 2013-08-20
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 4, Randomised, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 Compared with OROS-MPH with a Placebo Referance Arm, ...
    Medical condition: Attention-deficit/hyperactivity disorder is a psychiatric disorder characterized by developmentally inappropriate degrees of inattentiveness, impulsivity, and hyperactivity
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004873 10064104 ADHD LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended) HU (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024409-11 Sponsor Protocol Number: LSC-001 Start Date*: 2011-08-11
    Sponsor Name:Scottish National Blood Transfusion Service [...]
    1. Scottish National Blood Transfusion Service
    2. NHS Lothian
    Full Title: Pilot Clinical Assessment of Ex Vivo Expanded Corneal Limbal Stem Cell Transplantation in Patients with Severe Ocular Surface Disease (OSD) Arising from Limbal Stem Cell Deficiency
    Medical condition: Severe Ocular Surface Disease (OSD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10067103 Ocular surface disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004858-30 Sponsor Protocol Number: BAY94-9027/21824 Start Date*: 2022-09-05
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A phase 3, single group treatment, open-label, study to evaluate the safety of BAY 94-9027 infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years wit...
    Medical condition: Severe hemophilia A (<1% FVIII:C)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10060612 Hemophilia A LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: NO (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000821-29 Sponsor Protocol Number: SPD503-401 Start Date*: 2020-11-19
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab...
    Medical condition: Attention-deficit/hyperactivity disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Trial now transitioned) SE (Trial now transitioned) AT (Prematurely Ended) ES (Ongoing) BE (Ongoing) PT (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-006275-20 Sponsor Protocol Number: LP0074-33 Start Date*: 2012-08-20
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase II exploratory study evaluating the efficacy of topical cromoglicate solution(20mg/ml) compared to topical solution vehicle in the treatment of mastocytosis
    Medical condition: mastocytosis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10040785 - Skin and subcutaneous tissue disorders 10012812 Diffuse cutaneous mastocytosis PT
    15.0 10005329 - Blood and lymphatic system disorders 10056452 Indolent systemic mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003717-18 Sponsor Protocol Number: 215226/VIR-7831-5005 Start Date*: 2021-12-30
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An open-label, non-comparator, multicenter study to describe the pharmacokinetics (PK), pharmacodynamics (PD; viral load) and safety following a single intravenous or intramuscular dose of sotrovim...
    Medical condition: COVID-19 at high risk of disease progression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    23.1 10021881 - Infections and infestations 10084401 COVID-19 respiratory infection LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004415-37 Sponsor Protocol Number: NN8022-4179 Start Date*: 2015-11-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week dou...
    Medical condition: Obesity (Prader-Willi syndrome)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002787-27 Sponsor Protocol Number: ACP-001_CT-004 Start Date*: 2013-02-11
    Sponsor Name:Ascendis Pharma A/S
    Full Title: A multicenter, Phase 2, randomized, open label, active-controlled, parallel-group study investigating the safety, tolerability, and efficacy of different dose levels of ACP-001 administered once we...
    Medical condition: Growth Hormone Deficiency (GHD) in pre-pubertal children
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) GR (Completed) BG (Completed) SI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-004434-42 Sponsor Protocol Number: BAY94-9027/15912 Start Date*: 2013-04-15
    Sponsor Name:Bayer AG
    Full Title: A multi-center, phase III, non-controlled, open-label trial to evaluate the pharmacokinetics, safety, and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated chi...
    Medical condition: severe hemophilia A (<1% FVIII:C)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    20.0 10010331 - Congenital, familial and genetic disorders 10060612 Hemophilia A LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) NL (Completed) LT (Completed) BG (Completed) Outside EU/EEA PL (Completed) AT (Completed) NO (Ongoing) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005800-27 Sponsor Protocol Number: 204957 Start Date*: 2016-11-08
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, multi-center, double blind (sponsor open), placebo-controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GSK3117391 in subjects with ...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001785-17 Sponsor Protocol Number: GENA-13 Start Date*: 2011-09-27
    Sponsor Name:Octapharma AG
    Full Title: Clinical Study in Previously Treated Children with Severe Haemophilia A to Investigate the Long-Term Immunogenicity, Tolerability and Efficacy of Human-cl rhFVIII
    Medical condition: Severe Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed) FR (Completed) CZ (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-000854-24 Sponsor Protocol Number: VE-CIP2001/2021 Start Date*: 2021-12-21
    Sponsor Name:ALFASIGMA S.P.A.
    Full Title: Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial.
    Medical condition: Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture si...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004455-36 Sponsor Protocol Number: ATO-TS Start Date*: 2020-03-10
    Sponsor Name:CHU DE POITIERS
    Full Title: Evaluation of the effect of Atomoxetine on impulsive state of High impulsive Tourette’s patients.
    Medical condition: High impulsive Tourette’s syndrome patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10042808 Syndrome Gilles de la Tourette LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:01:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA